Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.53 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8814713 | 1.00 | KDM5A (0.53) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL15177356 | 1.00 | KDM5A (0.53) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL5274891 | 1.00 | KDM5A (0.53) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL4990375 | 0.98 | KDM5A (0.50) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL8025386 | 0.98 | KDM5A (0.51) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL17297348 | 0.98 | KDM5A (0.51) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL14262605 | 0.96 | KDM5A (0.49) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL9668398 | 0.92 | CYP1A2 (0.52) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL9978410 | 0.90 | KDM5A (0.49) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL8023937 | 0.90 | KDM5A (0.49) | KDM5APHF8KDM2AKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2015172047-A1 | CYCLIC PEPTIDE COMPOUNDS AND RELATED METHODS, SALTS AND COMPOSITIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | KDM5A 4252/4885PHF8 3940/4885KDM2A 4380/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | KDM5A 4252/4885PHF8 3940/4885KDM2A 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.